Arcturus Therapeutics
ARCT
53 hedge funds and large institutions have $65.7M invested in Arcturus Therapeutics in 2020 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 8 closing their positions.
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
31% more capital invested
Capital invested by funds: $50.1M → $65.7M (+$15.6M)
20% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 15
6% more funds holding
Funds holding: 50 → 53 (+3)
1.19% more ownership
Funds ownership: 30.08% → 31.28% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less call options, than puts
Call options by funds: $1.58M | Put options by funds: $1.81M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$3.35M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$2.31M |
| 3 |
Millennium Management
New York
|
+$1.28M |
| 4 |
Goldman Sachs
New York
|
+$667K |
| 5 |
Morgan Stanley
New York
|
+$557K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DI
DFPG Investments
Sandy,
Utah
|
-$1.79M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.55M |
| 3 |
Two Sigma Investments
New York
|
-$673K |
| 4 |
Squarepoint
New York
|
-$594K |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$574K |
ARCT Hedge Fund Activity: Q1 2020 in Review
53 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q1 2020, worth a combined $65.7M — up 31% from $50.1M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ARCT positions and 8 closed out — a net gain of 4 holders — while 18 added to existing stakes and 15 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $3.35M. The largest seller was DFPG Investments, cutting an estimated $1.79M.
- 53 institutional investors held Arcturus Therapeutics (ARCT) as of Q1 2020, up from 50 in Q4 2019.
- Funds reported $65.7M of Arcturus Therapeutics stock for Q1 2020, up 31% quarter-over-quarter.
- 12 funds opened new Arcturus Therapeutics positions in Q1 2020 and 8 closed out, a net change of +4 holders.
- The largest Arcturus Therapeutics buyer in Q1 2020 was Cormorant Asset Management, an estimated $3.35M added.
- The largest Arcturus Therapeutics seller in Q1 2020 was DFPG Investments, an estimated $1.79M sold.
Based on aggregated 13F filings for Q1 2020.